-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Primary liver cancer is abbreviated as liver cancer, which can be divided into three types: hepatocellular carcinoma, intrahepatic cholangiocarcinoma and mixed hepatocellular cholangiocarcinoma
.
China is the country with the largest number of incidences and deaths of liver cancer in the world
Primary liver cancer is abbreviated as liver cancer, which can be divided into three types: hepatocellular carcinoma, intrahepatic cholangiocarcinoma and mixed hepatocellular cholangiocarcinoma
According to the latest global cancer burden data released by the WHO International Agency for Research on Cancer in 2020 , China 's primary liver cancer incidence rate in China in 2020 ranks 5th in malignant tumors, and the mortality rate ranks 2nd.
Although the diagnosis and treatment technology of liver cancer has made great progress in recent years , the overall 5- year net survival rate of liver cancer patients in China has not improved significantly, and it lags far behind Europe, the United States, and even South Korea, Japan and other countries
.
Therefore, only by scientifically understanding the risk factors of liver cancer, identifying the high-risk groups of liver cancer, and standardizing the monitoring program, can the early detection, diagnosis and treatment of liver cancer be achieved, and the survival rate of liver cancer patients can be effectively improved
Despite recent liver cancer diagnosis technology it has made great progress, but in our country, liver cancer patients in general clinics in our country, patients with liver cancer in general in our country, patients with liver cancer overall 5 5 -year survival rate was no significant net increase, far behind Europe and even South Korea, Japan and other countries
Hepatitis B virus (HBV hepatitis B virus (HBV ) infection is the main cause of the high burden of liver cancer in China
This randomized, open-label Phase 2-3 study was conducted at 50 clinical sites
in China .
Aged 18 years or older with histologically or cytologically confirmed diagnosis or clinical patients with unresectable or metastatic liver cancer, not previously received systemic therapy, baseline eastern Cooperative Oncology Group ( ECOG ) performance status of 0 or 1 patients Eligible to be included
This randomized, open-label Phase 2-3 study was conducted at 50 clinical sites
Compared with the standard treatment of sorafenib (red line), the progression-free survival (A) and overall survival (B) of the cintilimumab combined with IBI305 group (blue line)
Compared with the standard treatment of sorafenib (red line), the progression-free survival (A) and overall survival (B) of the cintilimumab combined with IBI305 group (blue line)During 2019.
02.
11-2020.
01.
15 , 595 patients were
recruited .
Twenty-four people were directly selected for the Phase 2 safety run-in period, and 571 people were randomly assigned to the cintilimer - bevacizumab biosimilar ( n=380 ) or sorafenib ( n=191 )
During 2019.
Sim for Limo - bevacizumab group and biosimilars median follow-up time sorafenib group were 10.
In the first-line treatment of Chinese patients with unresectable HBV-related hepatocellular carcinoma, Sintilimox plus IBI305 showed obvious advantages in overall survival and progression-free survival
.
This combined treatment program can provide a new treatment option for such patients
.
In the first-line treatment of Chinese patients with unresectable HBV-related hepatocellular carcinoma, Sintilimox plus IBI305 showed obvious advantages in overall survival and progression-free survival
.
This combined treatment program can provide a new treatment option for such patients
.
In the first-line treatment of Chinese patients with unresectable HBV-related hepatocellular carcinoma, Sintilimox plus IBI305 showed obvious advantages in overall survival and progression-free survival
.
This combined treatment program can provide a new treatment option for such patients
.
references:
references:Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study.
https://doi.
org/10.
1016/S1470-2045(21)00252 -7
https://doi.
org/10.
1016/S1470-2045(21)00252 -7 Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study.
Leave a message here